Philip E.J. Sanderson

2.7k total citations · 1 hit paper
37 papers, 1.7k citations indexed

About

Philip E.J. Sanderson is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Philip E.J. Sanderson has authored 37 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 13 papers in Organic Chemistry and 9 papers in Oncology. Recurrent topics in Philip E.J. Sanderson's work include Blood Coagulation and Thrombosis Mechanisms (7 papers), Chemical Synthesis and Analysis (7 papers) and Peptidase Inhibition and Analysis (5 papers). Philip E.J. Sanderson is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (7 papers), Chemical Synthesis and Analysis (7 papers) and Peptidase Inhibition and Analysis (5 papers). Philip E.J. Sanderson collaborates with scholars based in United States, Canada and Italy. Philip E.J. Sanderson's co-authors include Wei Zheng, Ian Fleming, Wei Sun, David C. Parker, Rolf Henning, Paul Shinn, Gregory J. Tawa, W. Clark Still, Adolfo Garcı́a-Sastre and Jennifer Kouznetsova and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Cancer Research.

In The Last Decade

Philip E.J. Sanderson

37 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Drug combination therapy increases successful drug repositioning

2016 313 citations Wei Sun, Philip E.J. Sanderson et al. Drug Discovery Today profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philip E.J. Sanderson United States	20	652	609	301	188	148	37	1.7k
Tove Tuntland United States	25	482 0.7×	732 1.2×	151 0.5×	126 0.7×	142 1.0×	39	1.7k
Goutam Mukherjee India	22	481 0.7×	479 0.8×	114 0.4×	142 0.8×	84 0.6×	67	1.5k
Raman Sharma United States	27	413 0.6×	785 1.3×	233 0.8×	284 1.5×	151 1.0×	74	2.0k
Matthew Wright United States	25	342 0.5×	472 0.8×	171 0.6×	174 0.9×	90 0.6×	85	1.8k
Vincent S. Stoll United States	22	449 0.7×	743 1.2×	194 0.6×	130 0.7×	288 1.9×	49	1.5k
Daniel R. McMasters United States	22	373 0.6×	562 0.9×	187 0.6×	181 1.0×	98 0.7×	40	1.2k
Renate Griffith Australia	27	641 1.0×	1.0k 1.7×	110 0.4×	240 1.3×	44 0.3×	90	2.0k
Pankaj Kumar Singh India	30	772 1.2×	743 1.2×	122 0.4×	213 1.1×	117 0.8×	127	2.3k
Hon C. Hui United States	20	367 0.6×	580 1.0×	572 1.9×	70 0.4×	226 1.5×	25	1.3k
James W. Janc United States	22	287 0.4×	529 0.9×	169 0.6×	98 0.5×	104 0.7×	51	1.1k

Countries citing papers authored by Philip E.J. Sanderson

Since Specialization

Citations

This map shows the geographic impact of Philip E.J. Sanderson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip E.J. Sanderson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip E.J. Sanderson more than expected).

Fields of papers citing papers by Philip E.J. Sanderson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip E.J. Sanderson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip E.J. Sanderson. The network helps show where Philip E.J. Sanderson may publish in the future.

Co-authorship network of co-authors of Philip E.J. Sanderson

This figure shows the co-authorship network connecting the top 25 collaborators of Philip E.J. Sanderson. A scholar is included among the top collaborators of Philip E.J. Sanderson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip E.J. Sanderson. Philip E.J. Sanderson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shrimp, Jonathan H., John Janiszewski, Catherine Z. Chen, et al.. (2022). Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19. ACS Infectious Diseases. 8(6). 1191–1203. 6 indexed citations

Wang, Amy Q., Elias Carvalho Padilha, Mengbi Yang, et al.. (2022). Preclinical Pharmacokinetics and In Vitro Properties of GS-441524, a Potential Oral Drug Candidate for COVID-19 Treatment. Frontiers in Pharmacology. 13. 918083–918083. 16 indexed citations

Williams, Eleanor, Jana Bagarova, Georgina Kerr, et al.. (2021). Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva. JCI Insight. 6(8). 41 indexed citations

Shrimp, Jonathan H., Stephen C. Kales, Philip E.J. Sanderson, et al.. (2020). An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19. ACS Pharmacology & Translational Science. 3(5). 997–1007. 79 indexed citations

Jiang, Jian‐kang, Xiuli Huang, Khalida Shamim, et al.. (2018). Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 28(20). 3356–3362. 19 indexed citations

Sun, Wei, Shihua He, Carles Martínez‐Romero, et al.. (2016). Synergistic drug combination effectively blocks Ebola virus infection. Antiviral Research. 137. 165–172. 68 indexed citations

Patel, Paresma, Wei Sun, Xiuli Huang, et al.. (2016). In vitro evaluation of imidazo[4,5-c]quinolin-2-ones as gametocytocidal antimalarial agents. Bioorganic & Medicinal Chemistry Letters. 26(12). 2907–2911. 10 indexed citations

Sun, Wei, Philip E.J. Sanderson, & Wei Zheng. (2016). Drug combination therapy increases successful drug repositioning. Drug Discovery Today. 21(7). 1189–1195. 313 indexed citations breakdown →

Haskell, Kathleen, Bonnie J. Howell, Raymond C. F. Jones, et al.. (2010). An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo. Cancer Biology & Therapy. 9(7). 493–503. 53 indexed citations

10.

Lu, Wei, Lenora J. Davis, Gaozhen Hang, et al.. (2009). Abstract #3714: In vitro and in vivo antitumor activities of MK-2206, a new allosteric Akt inhibitor. Cancer Research. 69. 3714–3714. 11 indexed citations

11.

Lyle, Terry A., Daniel R. McMasters, Philip E.J. Sanderson, et al.. (2006). Discovery of potent, selective 4-fluoroproline-based thrombin inhibitors with improved metabolic stability. Bioorganic & Medicinal Chemistry. 14(20). 6900–6916. 31 indexed citations

12.

Sanderson, Philip E.J., Matthew G. Stanton, Bruce D. Dorsey, et al.. (2003). Azaindoles: moderately basic P1 groups for enhancing the selectivity of thrombin inhibitors. Bioorganic & Medicinal Chemistry Letters. 13(5). 795–798. 21 indexed citations

13.

Sanderson, Philip E.J., Adel M. Naylor-Olsen, Franklin C. Clayton, et al.. (2003). 3-Amino-4-sulfonylpyridinone acetamide and related pyridothiadiazine thrombin inhibitors. Bioorganic & Medicinal Chemistry Letters. 13(8). 1441–1444. 8 indexed citations

14.

Sanderson, Philip E.J., Julie A. Krueger, Lawrence C. Kuo, et al.. (2003). Small, low nanomolar, noncovalent thrombin inhibitors lacking a group to fill the ‘Distal binding pocket’. Bioorganic & Medicinal Chemistry Letters. 13(2). 161–164. 23 indexed citations

15.

Sanderson, Philip E.J.. (1999). Small, noncovalent serine protease inhibitors. Medicinal Research Reviews. 19(2). 179–197. 69 indexed citations

16.

Pasternak, Alexander, Yanping Pan, Philip E.J. Sanderson, et al.. (1999). Potent, orally bioavailable somatostatin agonists: Good absorption achieved by urea backbone cyclization. Bioorganic & Medicinal Chemistry Letters. 9(3). 491–496. 17 indexed citations

17.

Gardell, Stephen J. & Philip E.J. Sanderson. (1998). Novel anticoagulants based on direct inhibition of thrombin and factor Xa. Behavioural Pharmacology. 9(2). 75???82–75???82. 1 indexed citations

18.

Lewis, Sidney D., Bobby J. Lucas, Stephen F. Brady, et al.. (1998). Characterization of the Two-step Pathway for Inhibition of Thrombin by α-Ketoamide Transition State Analogs. Journal of Biological Chemistry. 273(9). 4843–4854. 9 indexed citations

19.

Sanderson, Philip E.J., Bruce D. Dorsey, Colleen M. McDonough, et al.. (1998). L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor. Bioorganic & Medicinal Chemistry Letters. 8(7). 817–822. 51 indexed citations

20.

Sanderson, Philip E.J., et al.. (1998). Thrombin Inhibitor Design. Current Medicinal Chemistry. 5(4). 289–304. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact